Clinically , phase II trials in T2DM patients demonstrate that umbilical cord-derived MSCs (UC-MSCs) reduce HbA1c by 1.5–2.0% and improve insulin sensitivity, correlating with decreased serum TNF-α and increased adiponectin levels (26) . This evidence concerns the gene INS and type 2 diabetes mellitus.